Menta Capital’s Haemonetics HAE Stock Holding History

Menta Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,725	Closed	-$427K	–	592
2018 Q3	$427K	Buy	+3,725	New	+$386K	0.15%	258
2018 Q2	–	Sell	-5,760	Closed	-$421K	–	690
2018 Q1	$421K	Sell	5,760 -4,265	-43%	-$293K	0.09%	379
2017 Q4	$582K	Sell	10,025 -17,600	-64%	-$927K	0.11%	325
2017 Q3	$1.24M	Sell	27,625 -22,926	-45%	-$953K	0.18%	191
2017 Q2	$2M	Buy	+50,551	New	+$2.08M	0.24%	123
2016 Q3	–	Sell	-45,900	Closed	-$1.33M	–	884
2016 Q2	$1.33M	Buy	45,900 +32,200	+235%	+$973K	0.18%	154
2016 Q1	$479K	Buy	+13,700	New	+$442K	0.07%	508
2015 Q4	–	Sell	-21,019	Closed	-$679K	–	898
2015 Q3	$679K	Buy	+21,019	New	+$791K	0.11%	348

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Menta Capital's HAE Position: Q4 2018 in Review

Menta Capital sold out of Haemonetics (HAE) in Q4 2018, closing a stake of 3,725 shares — an estimated $427K sold.

Menta Capital first reported a position in HAE in Q3 2015 and held it in 8 quarters. The position peaked at $2M in Q2 2017. 279 funds tracked by Wall St. Rank hold HAE as of Q4 2018.

Menta Capital reported no remaining Haemonetics position as of Q4 2018 after selling out during the quarter.
Menta Capital sold 3,725 Haemonetics shares in Q4 2018, an estimated $427K.
Menta Capital first reported a position in Haemonetics in Q3 2015 and held it in 8 quarters.
Menta Capital's Haemonetics position peaked at $2M in Q2 2017.
279 funds tracked by Wall St. Rank held Haemonetics as of Q4 2018.

Based on Menta Capital's 13F filing for Q4 2018, filed 14 Feb 2019.